Skip to main content
Mimi Hu, MD, Endocrinology, Houston, TX

MimiI-NanHuMD

Endocrinology Houston, TX

Diabetes, Osteoporosis & Bone Metabolism Medicine, Parathyroid, Thyroid

Professor Endocrine Neoplasia and Hormonal Disorders The University of Texas MD Anderson Cancer Center

Dr. Hu is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Hu's full profile

Already have an account?

  • Office

    1515 Holcombe Blvd, Unit 1461
    Houston, TX 77030
    Phone+1 713-792-2841

Education & Training

  • Baylor College of Medicine
    Baylor College of MedicineFellowship, Endocrinology, Diabetes, and Metabolism, 2004 - 2007
  • Baylor College of Medicine
    Baylor College of MedicineResidency, Internal Medicine, 2000 - 2004
  • McGovern Medical School at UTHealth
    McGovern Medical School at UTHealthClass of 2000

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2021 - Present
  • AZ State Medical License
    AZ State Medical License 2023 - 2026
  • TN State Medical License
    TN State Medical License 2023 - 2026
  • TX State Medical License
    TX State Medical License 2002 - 2026
  • WA State Medical License
    WA State Medical License 2023 - 2026
  • GA State Medical License
    GA State Medical License 2023 - 2025
  • LA State Medical License
    LA State Medical License 2023 - 2025
  • American Board of Internal Medicine Endocrinology, Diabetes and Metabolism
  • Join now to see all

Awards, Honors, & Recognition

  • Top Doctors:SE Texas Castle Connolly, 2013
  • Super Doctor SuperDoctors.com

Publications & Presentations

PubMed

Press Mentions

  • Preview of the 93rd American Thyroid Association Annual Meeting
    Preview of the 93rd American Thyroid Association Annual MeetingJuly 1st, 2024
  • Targeted Therapy Pralsetinib Safely Effectively Treats Lung and Thyroid Cancers with RET Alterations
    Targeted Therapy Pralsetinib Safely Effectively Treats Lung and Thyroid Cancers with RET AlterationsJune 9th, 2021
  • Gavreto Gets Accelerated Approval for RET-Altered Thyroid Cancers
    Gavreto Gets Accelerated Approval for RET-Altered Thyroid CancersDecember 3rd, 2020
  • Join now to see all

Professional Memberships